What Does a GLP-1 Medication Actually Cost on Medicare After July 2026?

Cost is the number one barrier that has kept Medicare beneficiaries from accessing GLP-1 weight loss medications. Wegovy costs roughly $1,300 per month at retail. Zepbound runs around $1,000. For most seniors on a fixed income, those numbers were simply not realistic. Starting July 1, 2026, the Medicare GLP-1 Bridge program changes the math — capping copays at $50 per month for eligible beneficiaries. This article breaks down exactly what you will pay, what hidden costs to watch for, and how the Bridge program pricing compares to other ways of accessing these medications.

The $50 per month copay cap explained

Under the Medicare GLP-1 Bridge program, the maximum you will pay out of pocket for a covered GLP-1 medication is $50 per month. This cap applies:

• Regardless of which covered medication you are prescribed (Wegovy, Zepbound, or Foundayo).
• Regardless of your dose level — the copay stays the same whether you are on a starting dose or a maintenance dose.
• At participating retail pharmacies (CVS, Walgreens, local independents, and others).
• For each monthly fill — this is a recurring monthly cost, not a one-time payment.

The $50 copay is the beneficiary share. The remaining cost of the medication is covered through the Bridge program funding structure under Medicare Part D.

What these medications cost without coverage

To understand what the Bridge program actually saves you, here is what these medications cost at retail without any insurance coverage:

• Wegovy (semaglutide 2.4 mg injection): approximately $1,300 to $1,400 per month.
• Zepbound (tirzepatide injection): approximately $1,000 to $1,100 per month.
• Foundayo (orforglipron, oral): pricing not yet widely established, but expected to be comparable to injectable options.
• Compounded semaglutide (not covered by the Bridge program): typically $200 to $500 per month through telehealth providers, but quality, dosing accuracy, and regulatory status vary widely.

The Bridge program represents savings of approximately $950 to $1,350 per month compared to retail pricing — or $11,400 to $16,200 per year.

Costs the Bridge program does not cover

The $50 copay covers the medication itself. There are other costs associated with starting and maintaining a GLP-1 that the program does not cover:

• Doctor visit copays — your regular Medicare Part B copays for office visits still apply. If your doctor charges for the initial evaluation and follow-up appointments, those costs are separate.
• Lab work — blood tests (A1C, lipid panels, metabolic panels) may be ordered before or during treatment. These are typically covered under Part B but may have copays depending on your plan.
• Nutritional supplements — protein shakes, fiber supplements, electrolyte products, and vitamins recommended to support your health on a GLP-1 are out-of-pocket expenses.
• Dietitian or nutritionist consultations — some Medicare Advantage plans cover these, but Original Medicare coverage is limited to specific diagnoses like diabetes.
• Gym memberships or exercise programs — not covered under Part D, though some Medicare Advantage plans include fitness benefits like SilverSneakers.

How the Bridge program compares to other options

If you are evaluating all available paths to access GLP-1 medications, here is how the Bridge program compares:

Bridge program vs. retail cash pay

Retail cash pay runs $1,000 to $1,400 per month for brand-name medications. The Bridge program reduces this to $50. There is no comparison if you qualify.

Bridge program vs. manufacturer savings cards

Novo Nordisk and Eli Lilly offer savings programs for commercially insured patients, but these programs typically exclude Medicare beneficiaries. The Bridge program is specifically designed for Medicare — it fills the gap that manufacturer cards do not.

Bridge program vs. compounded medications

Compounded semaglutide through telehealth platforms typically costs $200 to $500 per month. That is cheaper than brand-name retail, but still four to ten times more expensive than the Bridge program copay. Additionally, compounded medications are not FDA-approved and carry different quality and safety profiles. If you qualify for the Bridge program, brand-name medications at $50 per month are the stronger option both financially and clinically.

Bridge program vs. existing Part D diabetes coverage

If you have Type 2 diabetes, your Part D plan may already cover Ozempic or Mounjaro under the diabetes formulary — potentially with different copay tiers. The Bridge program is separate and covers medications prescribed specifically for weight management. If you have both diabetes and obesity, talk to your doctor about which coverage pathway and which medication is the best fit.

Will the $50 copay change over time?

The Bridge program is structured as a time-limited federal pilot. The $50 copay cap is set for the initial program period. Whether the program continues, expands, or adjusts its pricing depends on the outcomes data collected during the pilot and on future federal policy decisions.

If you are considering starting a GLP-1 medication through the Bridge program, the current pricing structure is the one to plan around. Waiting for potential future changes means missing months of treatment that could already be improving your health.

Budgeting for your first three months

Here is a realistic estimate of what the first three months on a GLP-1 through the Bridge program might cost, including expenses beyond the medication itself:

• GLP-1 medication: $50 per month ($150 total for three months).
• Doctor visits (initial evaluation plus one follow-up): approximately $30 to $60 in Part B copays, depending on your plan.
• Lab work (if ordered): typically covered under Part B with minimal copay.
• Protein supplements and electrolytes: approximately $30 to $60 per month if you choose to use them.
• Estimated total for three months: approximately $250 to $400.

Compare that to three months at retail without coverage: $3,000 to $4,200 for the medication alone.

Tracking costs alongside your health

When you are managing a monthly medication, follow-up appointments, and lifestyle adjustments on a fixed income, staying organized matters. Tracking what you eat, how you feel, and how your body responds is not just a health practice — it is also how you demonstrate to your prescriber that the medication is working, which strengthens your case for continued coverage.

CairnSpace provides a free daily check-in, meal logger, and symptom tracker designed for GLP-1 users. It takes about a minute a day and builds a clear record you can bring to your follow-up appointments. There is no subscription, no hidden fees, and no data selling — just a private tool to help you stay on track.

Sources

Information in this article is based on publicly available sources, including:

Related Articles

• Does Medicare Cover GLP-1 Weight Loss Medications in 2026?
• The Medicare GLP-1 Bridge Program: What It Is, Who Qualifies, and How to Enroll
• How to Talk to Your Doctor About GLP-1 Medications on Medicare

• Centers for Medicare and Medicaid Services (CMS) — Part D pricing structures and Bridge program announcements.
• GoodRx and retail pharmacy pricing data for Wegovy, Zepbound, and compounded semaglutide.
• Novo Nordisk and Eli Lilly patient assistance program terms and exclusions.
• Medicare.gov — beneficiary cost-sharing information for Part B and Part D.

Prices quoted are approximate and based on publicly reported figures as of May 2026. Your actual costs may vary based on your specific Part D plan, pharmacy, and location. Always confirm pricing with your pharmacy before filling a prescription.